The UBS Group research report quoted Hutchmed (China) (00013.HK) management stating that the timetable for the sale of Shanghai Hutchison Pharmaceuticals is on track, with the Trade expected to be completed in the first quarter of this year. Management indicated that this sale is expected to record an investment gain of 0.477 billion USD, and the cash obtained will help the company focus on the development of innovative therapies, particularly in the antibody-drug conjugate (ADCC) platform.

The firm expects the company to achieve sustainable profitability starting in 2025, with net profit expected to rise to 0.452 billion USD; however, the net profit forecasts for 2026 and 2027 have been revised down by 55.6% and 39.5% respectively. The firm has lowered the company's Target Price from 42.3 yuan to 38.7 yuan, maintaining a "Buy" rating.